Meta-analysis Of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors In Patients With Chronic Kidney Disease And Albuminuria
Chronic kidney disease (CKD) represents a frequent co-morbidity of type 2 diabetes mellitus (T2DM), affecting 30-50% of all patients, while diabetes is the leading cause of end-stage kidney disease (ESKD) worldwide.1,2 Vice versa, incidence rates of T2DM among patients with CKD are significantly higher compared to the general population.3 Sufficient glycemic control is required for all patients suffering from CKD and TDM; however, very strict control has been shown to increase all-cause mortality similarly to insufficient control.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, Konstantinos Imprialos, Michael Doumas Source Type: research
More News: Cardiology | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Sodium | Urology & Nephrology